Düsseldorf, GERMANY – December 18, 2025 – Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced the appointment of Dr. Daniel Gau as Chief Business Officer (CBO), effective immediately. In this strategic role, Dr. Gau will lead all partnership and business development activities while supporting the company’s fundraising initiatives.
Daniel brings more than two decades of experience in pharmaceutical licensing, mergers and acquisitions, and business development across leading global organizations. Throughout his career, he has demonstrated exceptional expertise in identifying strategic opportunities, driving corporate growth through partnerships and acquisitions, and successfully managing complex financial transactions in the life sciences industry.
His previous roles include Chief Operating Officer and Head of Business Development at Unicyte AG (an affiliate of Fresenius Medical Care), where he successfully executed Series A/B funding rounds, and senior positions at Merck KGaA managing a significant commercial portfolio. Daniel will continue to serve as Vice President at 2 Bridge NV and Eisbach Bio GmbH.
Daniel holds a Ph.D. in Natural Sciences from the German Cancer Research Center (DKFZ), University of Heidelberg and completed his biotechnology studies at the École Supérieure de Biotechnologie de Strasbourg in France.
“I am delighted to welcome Daniel to Algiax as our new Chief Business Officer,” said Ingo Lehrke, CEO of Algiax. “Daniel’s extensive experience in pharmaceutical licensing, fundraising, and corporate strategy will be invaluable as we expand our partnerships and strengthen our relationships with current and future investors. I am convinced that Daniel will play a pivotal role in advancing Algiax’s growth trajectory and creating significant value for all stakeholders.”
Daniel added, “I am honored to join Algiax at such a pivotal moment in the company’s development having achieved clinical proof-of-concept for a non-opioid AP-325. I look forward to working with Algiax’ exceptional team and shareholders to drive meaningful impact for patient with neuropathic pain.”